Overview

Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)

Status:
Active, not recruiting

Trial end date:
2024-09-30

Target enrollment:

Participant gender:

Summary

This research study is comparing two different combinations of androgen deprivation therapy (ADT) used together with radiation as a treatment for rising PSA after radical prostatectomy (prostate cancer).

Phase:

Phase 2

Details

Lead Sponsor:

Dana-Farber Cancer Institute

Collaborator:

Janssen Pharmaceutica

Treatments:

Abiraterone Acetate
Bicalutamide
Prednisone